Tvardi Therapeutics Inc., a Houston, Texas-based clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, completed a $9m Series A financing round.
The backers were not disclosed.
The company intends to use the funds to complete an ongoing Phase 1 studies for its lead compound TTI-101 in solid tumor cancers, and complete IND-enabling studies of a second product for use in non-cancer indications, including cachexia.
Founded in 2017 by Ronald DePinho M.D., Director and Professor & Past President of MD Anderson Cancer Center, and David Tweardy M.D., President and Head of Internal Medicine at MD Anderson Cancer Center, a physician-scientist recognized for his research in STAT3 and its role in cancer, fibrosis and inflammation, Tvardi is a biopharmaceutical company focused on the development of inhibitors to STAT3, a key signaling molecule positioned at the intersection of many signaling pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions.
FinSMEs
24/09/2018